東阿阿膠(000423.SZ)擬轉讓華潤昂德生物25%股權予華潤生物醫藥
格隆匯 8 月 25日丨東阿阿膠(000423.SZ)公佈,為優化資源配置、提升目前經營效率和效益,公司擬與華潤生物醫藥(深圳)有限公司(“華潤生物醫藥”)簽訂《股權轉讓協議》,將華潤昂德生物藥業有限公司(“華潤昂德生物”)25%股權轉讓給華潤生物醫藥。基於該評估結果並經雙方協商,此次交易價格以評估結果乘以股權交易比例25%確定,公司此次轉讓華潤昂德生物25%股權的價格為7440.8425萬元人民幣,交易定價公允。
此次關聯交易對公司總體收益影響不大,且能夠回收股權投資資金7440.8425 萬元人民幣,增加公司現金流。此次關聯交易體現了公平、協商、一致的原則,價格公允合理,不會對公司財務狀況、經營成果造成不利影響,不存在損害公司和股東利益的情況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.